Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB26FSV01
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $47,823
Award facts
- Contract value 100% obligated
- $47,823.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $47,823.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The contract was awarded on November 6, 2025, with an ultimate completion date of November 7, 2025, under firm fixed-price terms and without a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional pharmaceutical prime vendors supporting Department of Defense medical supply needs.
DMS Pharmaceutical Group has demonstrated substantial contracting capacity as a critical supplier within the federal pharmaceutical supply chain, with recent delivery orders spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals distributed to military healthcare facilities. The company's PPV-G GEN V prime vendor contract, awarded November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. This contract positions DMS Pharmaceutical Group to serve as one of multiple regional prime vendors supplying the diverse and specialized pharmaceutical requirements of the Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FSV01?
SPE2DB26FSV01 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DB26FSV01 worth?
The government has obligated $47,823 on SPE2DB26FSV01.
Is contract SPE2DB26FSV01 an order under another contract?
Yes. SPE2DB26FSV01 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSV01 competed?
The extent of competition for SPE2DB26FSV01 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award